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paricalcitol was seen even in subjects 
already treated with ACEIs or ARBs, indi-
cating that the vitamin D analog has addi-
tive or synergistic eff ects with ACEIs / ARBs 
in reducing proteinuria. In a randomized 
double-blind pilot trial, Alborzi  et al. 16 
reported that paricalcitol treatment for 1 
month signifi cantly reduced albuminuria 
and inflammatory status in the drug-
treated subjects, and these eff ects were 
independent of its eff ects on hemodynam-
ics and parathyroid hormone suppression. 
Th e anti-albuminuric eff ect of vitamin D 
analogs is of particular signifi cance, as 
albuminuria is a major risk factor for the 
progressive decline of renal function and 
is believed to harbinger an inevitable pro-
gression to overt proteinuria and renal 
failure. Th us, reduction of albuminuria is 
a convincing and favorable eff ect during 
renoprotective therapy. 
 Trandolapril treatment markedly 
increased renin levels in the kidney. Yet 
combination treatment with trandolapril 
and paricalcitol markedly attenuated the 
induction of renin and Ang II. Th us, in 
the combination therapy, paricalcitol 
blocked the increase in renin, minimizing 
the Ang II-independent activation of the 
prorenin / renin receptor, which may also 
contribute to renal damage. Together 
these actions of the combination therapy 
lead to an eff ective strategy to counter the 
development of CKD. 
 Th e renoprotective eff ect of paricalcitol, 
however, appears to be not limited to the 
regulation of the RAS. Th e anti-infl amma-
tory properties of vitamin D and its 
analogs may further enhance their 
renoprotective eff ects in kidney disease. 
Th is study off ers new insights into a novel 
therapeutic approach for further clinical 
studies. Given the limitations of animal 
models, whether this therapeutic strategy 
also works in humans requires further 
clinical investigations. 
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 Gene  identification via positional 
cloning represents a form of deliberate 
ascertainment bias. Of necessity, 
researchers study families with extreme 
forms of disease to maximize the ability 
of these studies to succeed. In studies of 
dominantly inherited phenotypes, for 
example, it is typically through the study 
of large, multigenerational pedigrees 
with high penetrance that geneticists can 
home in on a narrowly defi ned genetic 
locus, and ultimately a single mutant 
gene. Although recessive families typi-
cally do not present as multigenerational, 
extended pedigrees (except in the pres-
ence of signifi cant inbreeding), it is sim-
ilarly typical for the initial success in a 
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 Expanding the spectrum 
of  NPHS1 -associated disease 
 Martin R.  Pollak 1 
 The nephrin gene  NPHS1  was cloned in 1998. Studies in families with 
congenital nephrotic syndrome led to the identification of this critical 
component of the glomerular slit diaphragm. Studies such as the new 
one by Sant í n  et al. are expanding our understanding of the spectrum of 
disease associated with  NPHS1 mutations. 
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disease gene identifi cation study to come 
from large families with fully penetrant, 
early-onset disease. Because it is the 
more extreme phenotypes that are most 
easily recognized by clinicians, and 
because these families are the most likely 
to lead to successful studies, our under-
standing of the full spectrum of mutant 
alleles, and the associated phenotypes, is 
likely to be incomplete. Recent studies 
have indeed suggested that the spectrum 
of  NPHS1 -associated disease is broader 
than originally appreciated. 
 NPHS1 , the gene encoding nephrin, 
was identified through the study of 
so-called congenital nephrotic syn-
drome of the Finnish type. 1,2 Although 
congenital nephrotic syndrome is 
observed worldwide, it is particularly 
common in Finland, where two founder 
mutations, both of which lead to trun-
cated protein products, are common. 
Children with congenital nephrotic 
syndrome and two mutant  NPHS1 alle-
les are born (often prematurely) with 
massive proteinuria and hypoalbumine-
mia.  NPHS1 is not the only congenital 
nephrotic syndrome gene. Mutations in 
 NPHS2 ,  WT1 , and  LAMB2 can also 
present with neonatal nephrosis that is 
not distinguishable from  NPHS1  -
 associated disease on clinical grounds. 3 
 Th e  NPHS1 product nephrin is an inte-
gral membrane protein of approximately 
185  kDa that interacts directly with the 
NPHS2 product podocin and has structural 
as well as signaling functions ( Figure 1 ). 
Over the past decade, the identifi cation of 
nephrin has led to a tremendous growth 
of knowledge regarding podocyte biol-
ogy, much too vast to summarize here in 
any detail. 4 
 Meanwhile, our knowledge of the 
spectrum of disease-associated  NPHS1 
variation has also continued to increase. 5 
 NPHS1 mutations can lead to a trun-
cated nephrin protein, as is the case with 
the two major mutations seen in Fin-
land, or cause defects in nephrin traf-
f ick ing to  the  ce l l  membrane.  6 
Occasionally, a severe nephrotic syn-
drome phenotype appears to be the 
result of mutations in both  NPHS1 and 
 NPHS2 in the same individual. 7 
 Although  NPHS1 was originally cloned 
by virtue of its role in causing congenital 
nephrosis, and  NPHS2 was cloned by 
virtue of its underlying a form of child-
hood-onset steroid-resistant nephrotic 
syndrome, there is considerable overlap in 
the spectrum of disease associated with 
mutations in these two genes. A sizable 
fraction of congenital nephrotic syndrome 
appears to be caused by mutations in both 
podocin alleles. 3 Conversely, nephrin 
mutations can cause childhood-onset 
disease. Last year, Philippe  et al. analyzed 
DNA from 142 families (160 patients) 
with nephrotic syndrome presenting aft er 
3 months of age. 8 Putative disease-causing 
nephrin mutations were found in 10 fam-
ilies, with the age of onset ranging from 
6 months to 8 years. 
 Sant í n  et al. 9 (this issue) report a sim-
ilar study of 97 focal segmental glomer-
ulosclerosis patients from 89 unrelated 
families. The authors report disease-
causing  NPHS1 defects in seven sporadic 
and five familial cases of disease. 
Although the ages of most of these 
patients are quite young, three of the 
individuals with apparently disease-
causing  NPHS1 mutations were 1 year of 
age or older, and one individual was 27 
years old at the time of disease onset. 
Th is observation further expands the 
clinical phenotypes associated with 
mutations in this gene. 
 As genes are resequenced at increasing 
frequencies in increasing sample sizes, 
new interpretive problems will emerge. 
How do we decide whether a newly iden-
tifi ed genetic variant is in fact contribut-
ing to disease? Just because a variant is 
rare and is found in patients with a phe-
notype of interest is, in general, not 
suffi  cient evidence. Perhaps such vari-
ants are common in the general popula-
tion, and only a subset of these variants 
are actually signifi cant biologically and 
clinically. Th is is less of a problem with 
genes such as  NPHS1 that were identi-
fi ed through linkage analysis in a large 
collection of well-phenotyped families. 
But if care is not taken, we will end up 
with a fl urry of non-reproducible results, 
as was the case in the early days of 
genetic associat ion studies (pre 
 ‘ GWAS ’ ). 10  Th e resequencing of genes 
is rapidly becoming easier. So-called 
next-generation DNA sequencing tech-
nology is just now in its infancy. 11 In the 
not too distant future, we will see studies 
using data from whole-genome DNA 
sequencing. We will need to exercise 
caution in its interpretation. 
 Meanwhile, studies such as the one by 
Sant í n  et al. 9 will help expand our appre-
ciation of the phenotypic and allelic com-
plexity of  ‘ simple ’ monogenic disorders. 
A better understanding of the spectrum 
and clinical consequences of  NPHS1 
mutations should continue to inform our 
understanding of pathobiology, and even-
tually, we hope, treatment. 
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 Figure 1  |  The glomerular slit diaphragm. Nephrin, the  NPHS1 gene product, helps to form 
the glomerular slit diaphragm complex. Mutations in  NPHS1 can lead to congenital nephrotic 
syndrome as well as later-onset nephrotic syndrome and focal segmental glomerulosclerosis. 
(Adapted with permission from ref.  12 .) 
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 Some time ago the transplantation   com-
munity moved past the notion that 
rejection is mediated exclusively via 
direct invasion of activated immune cells, 
that is, cytotoxic T lymphocytes in the 
allograft . Instead, acute cellular rejection 
is now known to oft en be accompanied 
by antibody-mediated phenomena, 
although occasionally antibody- mediated 
rejection can occur in the absence of 
acute cellular rejection. Th e antibodies 
involved in these phenomena were ini-
tially identifi ed as targeting donor human 
leukocyte antigen (HLA ) and causing 
damage by activating complement. Th is 
discovery resulted in techniques to better 
diagnose and characterize these anti-
body-mediated processes — for example, 
identifi cation of donor-specifi c antibod-
ies and titer quantifi cation in recipient 
sera. As well as staining of biopsy tissue 
for C4d . 
 Recently, it has become increasingly 
clear that antibodies not directed against 
donor HLA and not causing  complement-
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 Protein kinase C  : not-so-innocent 
bystander or unusual suspect 
in kidney transplant rejection ? 
 Jens W.D.  Goebel 1  
 Antibodies against non-HLA targets are increasingly recognized in the 
context of transplant rejection. However, their specific role remains 
largely elusive, as evidence exists supporting both their occurrence as 
an epiphenomenon and their actual pathogenicity in the rejection 
process. Sutherland  et al. describe protein kinase C  as a novel, non-HLA 
antigenic target in the setting of graft rejection. 
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mediated lysis of target tissues may also 
play roles in the pathogenesis of acute and 
chronic graft  damage. 1 Sutherland  et al. 2 
(this issue) present work that elaborates 
on this concept. Using protein microarray 
technology, they screened 15 pediatric 
kidney transplant recipients with acute 
cellular rejection (several with concomi-
tant evidence of antibody-mediated phe-
nomena, that is, positive C4d staining, 
detectable donor-specifi c antibodies, or 
antibodies directed against HLA that was 
not donor-specifi c) for  de novo antibodies 
against 5056 potentially antigenic protein 
targets. Th ey found  de novo antibody for-
mation against 229 non-HLA proteins, 
with antibodies against 36 of these targets 
detectable in more than one of the 
patients with rejection. Of all observed 
antibody responses, the strongest 
occurred against protein kinase C  
(PKC  ) in three individuals. While C4d 
staining was negative in the biopsies of 
these patients, they had particularly recal-
citrant clinical courses, and two of them 
lost their transplants within 2 years. In 
contrast, none of the 12 other patients 
with rejection but without a strong anti-
PKC  response experienced graft loss 
during follow-up. 
 Th e authors interpret their fi ndings 
with appropriate caution given their 
relatively small patient-sample size and 
the retrospective structure of their 
study. Although they consider detecta-
ble anti-PKC  to be a likely marker for 
rejection associated with poor graft 
 survival, they do not believe that it is a 
pathogenic antibody. This notion of 
anti-PKC  as a bystander is at least in 
part based on the authors ’ inability to 
detect C4d in the transplant biopsies of 
the rejection patients with a strong anti-
PKC   response. Accordingly, they 
hypothesize that, in these patients, 
severe renal injury and cell death led to 
PKC  exposure and subsequent anti-
body formation ( Figure 1 , top). 
 Could anti-PKC  be a novel mediator 
of an unusually aggressive subtype of 
rejection? Th is would be possible, if anti-
PKC  antibodies were activating simi-
larly to those against angiotensin II 
receptors described by Dragun  et al. 3 
PKC  plays critical roles in immune sig-
naling pathways, 4,5 and its excessive 
